Amgen Inc. (NASDAQ:AMGN) Position Reduced by Annex Advisory Services LLC

Annex Advisory Services LLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 11.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,768 shares of the medical research company's stock after selling 2,027 shares during the quarter. Annex Advisory Services LLC's holdings in Amgen were worth $4,110,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. XTX Topco Ltd acquired a new stake in Amgen in the 2nd quarter valued at approximately $661,000. AE Wealth Management LLC grew its stake in shares of Amgen by 33.1% in the second quarter. AE Wealth Management LLC now owns 19,241 shares of the medical research company's stock worth $6,012,000 after acquiring an additional 4,789 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Amgen by 8.9% in the second quarter. Pacer Advisors Inc. now owns 74,039 shares of the medical research company's stock valued at $23,133,000 after acquiring an additional 6,048 shares in the last quarter. Summit Trail Advisors LLC boosted its holdings in Amgen by 4.5% in the second quarter. Summit Trail Advisors LLC now owns 5,389 shares of the medical research company's stock valued at $1,684,000 after purchasing an additional 231 shares during the period. Finally, Profund Advisors LLC grew its stake in Amgen by 9.2% during the 2nd quarter. Profund Advisors LLC now owns 61,993 shares of the medical research company's stock worth $19,370,000 after purchasing an additional 5,248 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. William Blair reissued an "outperform" rating on shares of Amgen in a research report on Tuesday, November 12th. Redburn Partners dropped their price objective on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Wells Fargo & Company dropped their target price on Amgen from $335.00 to $280.00 and set an "equal weight" rating on the stock in a report on Friday, January 10th. TD Cowen upped their price objective on Amgen from $381.00 to $383.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Finally, Jefferies Financial Group restated a "buy" rating and set a $380.00 target price on shares of Amgen in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amgen has an average rating of "Hold" and an average target price of $314.91.

Amgen Trading Up 1.0 %

Shares of AMGN stock traded up $2.68 during mid-day trading on Monday, reaching $272.11. The company's stock had a trading volume of 3,244,015 shares, compared to its average volume of 3,140,853. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a market capitalization of $146.27 billion, a PE ratio of 34.84, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56. The company's 50 day simple moving average is $273.95 and its 200-day simple moving average is $307.18. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company's revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter last year, the firm earned $4.96 earnings per share. On average, research analysts predict that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is a boost from Amgen's previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.50%. Amgen's payout ratio is 121.90%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.